文献速递肺外科

新辅助化免治疗后肺癌切除的患者报告症状与心理困扰评估

Assessment of patient-reported symptom and psychological distress after neoadjuvant chemo-immunotherapy and lung resection for non-small cell lung cancer.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2026-01-01

本研究评估局部晚期非小细胞肺癌(NSCLC)患者在新辅助化疗联合免疫治疗(CT-IO)后接受肺切除的患者报告躯体症状与心理困扰,并与同期未行新辅助治疗的同期别手术患者比较。共82例完成调查,术后至访谈中位时间13.9个月,两组NSCLC-SAQ总分、焦虑抑郁评分及症状自评改善比例均相似。结论认为新辅助化免治疗在中长期随访中未对患者报告的身心症状产生负面影响。

要点

  • 新辅助化免后手术与直接手术的患者报告症状总分无差异(P = .64)。
  • 两组焦虑与抑郁平均评分相似,心理困扰未见增加。
  • 结果可用于向拟行新辅助化免治疗的患者进行咨询告知。

核心结论

  • 真实临床实践显示,与单纯手术相比,新辅助化疗联合免疫治疗在中长期随访中未对患者报告的躯体或心理症状产生负面影响。

研究设计与样本

  • 症状评估采用非小细胞肺癌症状评估问卷(NSCLC-SAQ),心理困扰评估采用医院焦虑抑郁量表(HADS)。

主要发现

  • 直接手术组(S)与新辅助化免后手术组(CT-IO)的NSCLC-SAQ总分无差异(P = .64)。
  • 多因素回归分析中,化疗联合免疫治疗与NSCLC-SAQ总分无独立关联。
  • 两组焦虑与抑郁平均评分相似。
  • 两组报告症状与治疗前相似或更好的患者比例相似。

关键数值与推荐

  • NSCLC-SAQ总分组间比较P = .64。

临床怎么用

  • 可将该结果作为患者咨询信息工具,告知新辅助化免联合手术在中长期患者报告症状与心理困扰方面与单纯手术相当。

局限性

  • 初筛138例中仅82例完成调查,存在未参与者的选择偏倚可能。
  • 为单中心真实世界观察性设计,非随机对照。
  • 随访为术后中位13.9个月的中长期,未覆盖更长期结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Neoadjuvant chemo-immunotherapy is associated with oncologic benefits in patients undergoing resection for locally advanced non-small cell lung cancer (NSCLC). We assessed patient-reported physical and psychological symptoms following neoadjuvant chemo-immunotherapy and surgery compared to stage-equivalent patients who were operated during the same period without neodjuvant treatment. METHODS: All consecutive patients submitted to lung resection for clinical stage II and III NSCLC between March 2023 and December 2024 and alive at the time of the interview were approached for the study. Their patient-reported symptoms were assessed using the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) and their psychological distress was assessed using the Hospital Anxiety and Depression Scale (HADS). RESULTS: Of the 138 patients initially screened, 82 completed the survey. Median time from surgery to the interview was 13.9 months. There was no difference in total NSCLC-SAQ score between patients undergoing upfront surgery (S) and surgery after neoadjuvant chemo-immunotherapy (CT-IO) (P = .64). Chemo-immunotherapy was not independently associated with total NSCLC-SAQ score after multivariable regression analysis. The average anxiety and depression scores were also similar between the 2 groups. Finally, a similar proportion of patients in the 2 groups reported to have symptoms similar or better than before starting treatment. CONCLUSIONS: Our findings show in a real clinical practice setting that neoadjuvant chemo-immunotherapy is not negatively associated with patient-reported physical or psychological symptoms in the medium to long-term follow-up compared to surgery alone. These results can be used as information tool during patients' counselling.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Pompili C, Tariq J, Bhatnagar P, et al. Assessment of patient-reported symptom and psychological distress after neoadjuvant chemo-immunotherapy and lung resection for non-small cell lung cancer. Interdiscip Cardiovasc Thorac Surg. 2026. PMID: 41506891. doi:10.1093/icvts/ivag003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。